Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lapatinib Ditosylate

FDA-approved product (tablet, oral), marketed as Lapatinib Ditosylate, Tykerb.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lapatinib Ditosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • HER2 Positive Breast Carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lapatinib Ditosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lapatinib Ditosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

    NCT00903656 · start 2009-05

    Registered record
    Registry ID
    NCT00903656
    Conditions
    Metastatic Breast Cancer
    Interventions
    doxorubicinhydrochloride, Lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-05
    Completion
    2012-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    Interventiondoxorubicinhydrochloride, Lapatinib
    PhasePhase 2
    Registry statusTerminated

  • Lapatinib in Combination With Vinorelbine

    NCT01128543 · start 2009-04

    Registered record
    Registry ID
    NCT01128543
    Conditions
    Cancer
    Interventions
    lapatinib and Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-04
    Completion
    2012-03
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    Interventionlapatinib and Vinorelbine
    PhasePhase 2
    Registry statusCompleted

  • Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

    NCT00841828 · start 2009-02

    Registered record
    Registry ID
    NCT00841828
    Conditions
    Breast Cancer
    Interventions
    Epirubicin; Cyclophosphamide; Docetaxel; Lapatinib; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-02
    Completion
    2013-12
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionEpirubicin; Cyclophosphamide; Docetaxel; Lapatinib +1 more
    PhasePhase 2
    Registry statusCompleted

  • Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

    NCT00842998 · start 2009-02

    Registered record
    Registry ID
    NCT00842998
    Conditions
    Metastatic Breast Cancer
    Interventions
    Trastuzumab or Lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-02
    Completion
    2011-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionTrastuzumab or Lapatinib
    PhasePhase 2
    Registry statusUnknown

  • Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803

    NCT00897351 · start 2008-07-10

    Registered record
    Registry ID
    NCT00897351
    Conditions
    Prostate Cancer
    Interventions
    mutation analysis; polymorphism analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-07-10
    Completion
    2009-02-10
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionmutation analysis; polymorphism analysis; protein expression analysis; immunohistochemistry staining method +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer

    NCT00721630 · start 2008-07

    Registered record
    Registry ID
    NCT00721630
    Conditions
    Breast Cancer
    Interventions
    capecitabine, lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-07
    Completion
    2016-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventioncapecitabine, lapatinib
    PhasePhase 2
    Registry statusCompleted

  • Lapatinib and Trastuzumab With or Without Endocrine Therapy

    NCT00548184 · start 2008-05

    Registered record
    Registry ID
    NCT00548184
    Conditions
    Breast Cancer
    Interventions
    Lapatinib; Trastuzumab; Endocrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-05
    Completion
    2014-01
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionLapatinib; Trastuzumab; Endocrine
    PhasePhase 2
    Registry statusCompleted

  • Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

    NCT00479856 · start 2007-11

    Registered record
    Registry ID
    NCT00479856
    Conditions
    Relapsed Breast Cancer; Neoplasms, Breast
    Interventions
    Lapatinib; Capecitabine; Docetaxel; nab-Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-11
    Completion
    2010-03
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Breast Cancer; Neoplasms, Breast
    InterventionLapatinib; Capecitabine; Docetaxel; nab-Paclitaxel
    PhasePhase 2
    Registry statusTerminated

  • Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

    NCT00536809 · start 2007-09-26

    Registered record
    Registry ID
    NCT00536809
    Conditions
    Neoplasms, Colorectal
    Interventions
    lapatinib; oxaliplatin; capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09-26
    Completion
    2008-10-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms, Colorectal
    Interventionlapatinib; oxaliplatin; capecitabine
    PhasePhase 1
    Registry statusCompleted

  • PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

    NCT00499681 · start 2007-07

    Registered record
    Registry ID
    NCT00499681
    Conditions
    Breast Cancer
    Interventions
    lapatinib ditosylate; letrozole; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-07
    Completion
    2010-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionlapatinib ditosylate; letrozole; placebo
    PhasePhase 2
    Registry statusTerminated

  • Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

    NCT00436566 · start 2007-03-16

    Registered record
    Registry ID
    NCT00436566
    Conditions
    Breast Cancer; Cardiac Toxicity
    Interventions
    trastuzumab; cyclophosphamide; doxorubicin hydrochloride; lapatinib ditosylate; paclitaxel; gene expression analysis; reverse transcriptase-polymerase chain reaction; fluorophotometry; laboratory biomarker analysis; mass spectrometry; adjuvant therapy; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03-16
    Completion
    2019-07-22
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Cardiac Toxicity
    Interventiontrastuzumab; cyclophosphamide; doxorubicin hydrochloride; lapatinib ditosylate +8 more
    PhasePhase 2
    Registry statusCompleted

  • Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

    NCT00482391 · start 2007-03

    Registered record
    Registry ID
    NCT00482391
    Conditions
    Breast Cancer
    Interventions
    trastuzumab; cyclophosphamide; doxorubicin hydrochloride; lapatinib ditosylate; paclitaxel; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2011-07
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiontrastuzumab; cyclophosphamide; doxorubicin hydrochloride; lapatinib ditosylate +2 more
    PhasePhase 2
    Registry statusCompleted

  • S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

    NCT00352443 · start 2006-09

    Registered record
    Registry ID
    NCT00352443
    Conditions
    Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    everolimus; lapatinib ditosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-09
    Completion
    2013-09
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Unspecified Adult Solid Tumor, Protocol Specific
    Interventioneverolimus; lapatinib ditosylate
    PhasePhase 1
    Registry statusCompleted

  • Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer

    NCT00429299 · start 2006-08

    Registered record
    Registry ID
    NCT00429299
    Conditions
    Neoplasms, Breast
    Interventions
    lapatinib; trastuzumab; paclitaxel; fluorouracil; epidoxorubicin; cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2012-06
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms, Breast
    Interventionlapatinib; trastuzumab; paclitaxel; fluorouracil +2 more
    PhasePhase 2
    Registry statusCompleted

  • Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

    NCT00320385 · start 2005-11

    Registered record
    Registry ID
    NCT00320385
    Conditions
    Neoplasms, Breast
    Interventions
    Lapatinib; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-11
    Completion
    2010-10
    Enrolment
    296

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms, Breast
    InterventionLapatinib; Trastuzumab
    PhasePhase 3
    Registry statusCompleted